Credit Rating
Intimation of Revision in Credit Ratings of Marksans Pharma Limited by Fitch Group.05-01-2018
05-01-2018
Change in Directorate
Sub: Change in Director Dear Sir, This is to inform you that Mr. Naresh Balwant Wadhwa (DIN: 01999073), has resigned as a Director of the Company with effect from 2nd January, 2018. You are requested to note the above in your records.02-01-2018
Closure of Trading Window
This is to inform you that the Meeting of the Board of Directors of the Company will be held on Monday, 13th November, 2017 at Mumbai, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 30th September, 2017. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares will remain closed for the Company's insiders...02-11-2017
Board Meeting On 13.11.2017
This is to inform you that the Meeting of the Board of Directors of the Company will be held on Monday, 13th November, 2017 at Mumbai, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 30th September, 2017.02-11-2017
Reg. 40(9) Of SEBI(LODR)Regulations, 2015 For The Half Year Ended 30.09.2017.
Reg. 40(9) of SEBI(LODR)Regulations, 2015 for the half year ended 30.09.2017.26-10-2017
Shareholding for the Period Ended September 30, 2017
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here17-10-2017
Compliance Certificate For The Period 30Th September, 2017
Compliance Certificate for the period 30th September, 201716-10-2017
Statement Of Investor Complaints For The Quarter Ended 30Th September, 2017 Under Regulation 13(3) Of SEBI (LODR), 2015.
Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below a statement of Investor complaints for the quarter ended 30th September, 2017. 1. Pending at the beginning of the quarter- 0 2. Received during the quarter- 3 3. Resolved during the quarter- 3 4. Pending to be resolved at the end of the quarter- 011-10-2017